THE-OPEN-GROUP
25.4.2022 14:02:17 CEST | Business Wire | Press release
The Open Group, the vendor-neutral technology consortium, today announced the release of the TOGAF® Standard, 10th Edition, marking a major milestone in the development of the world’s most widely-used Enterprise Architecture framework. Developed by The Open Group Architecture Forum, today’s release introduces a refreshed modular structure which will make it easier to apply the TOGAF framework to different kinds of organizations and styles of architecture.
Building on over twenty-five years of development and constant input from the forum’s global community of EA thought leaders, the TOGAF® Standard, 10th Edition expands the material available to architecture practitioners to make adoption of best practices easier. With greatly expanded guidance and “how-to” material, it enables organizations to operate in an efficient and effective way across a broad range of use-cases, including Agile enterprises and Digital Transformation.
The modular structure provides Enterprise Architects with greater guidance, and simpler navigation, for applying the TOGAF framework alongside its comprehensive fundamental knowledge base. By framing the knowledge base and the topic-specific guidance as separate, formal parts of the TOGAF Standard, the new release will also make it possible to release additional material more frequently while maintaining continuity and stability in its fundamental content.
“The Open Group shares a collective vision of Boundaryless Information Flow™, and the release of the TOGAF® Standard, 10th Edition is a powerful expression of that vision”, commented Steve Nunn, CEO and President of The Open Group. “The next decade of technology and business pressures will require organizations to be more agile, resilient, and adaptable than ever, and that will make a clear approach to architecture more important than ever. I am proud of what The Open Group Architecture Forum has produced for this release, which makes the TOGAF framework significantly more usable by even more businesses while maintaining its core values of consistency, openness, and efficiency.”
“The TOGAF Standard, 10th Edition shows you where to find enduring and universal concepts. It highlights where to find stable, proven best practice. It underscores where to look for new emerging ideas. Bringing together universal concepts, best practice guidance, and emerging ideas is how you adapt the TOGAF Standard for your configured Enterprise Architecture practice,” commented Chris Forde, VP Enterprise Architecture of The Open Group.
The TOGAF® Standard, 10th Edition continues to grow the framework’s ability to enable fundamental aspects of business strategy. These enhancements will also benefit vendors in terms of their ability to deliver competitive new features and services to customers in specialized market segments while adhering to open standards which underpin interoperability.
“The fact that the TOGAF Standard is a living body of knowledge is one of its great advantages,” continued Steve Nunn. “We have now arrived at a point where business strategy and digital solutions are inseparable, and organizations of every size, in every sector, face the need to establish Agile ways of working which continually evolve and adapt. The TOGAF® Standard, 10th Edition shows how the TOGAF ecosystem is itself adapting to this reality, growing with businesses to deliver significant value in times of change.”
- ENDS -
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 870 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
